Physician profile
Asya Benin
NPI 1326111550
$1,740.37
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $398 · 2021: $466 · 2022: $357 · 2023: $135 · 2024: $53.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $188.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $201.39 | 2019-2022 | |
| Pfizer INC. | $174.83 | 2020-2021 | |
| Abbvie INC. | $167.61 | 2021-2024 | Viberzi, Linzess |
| Amarin Pharma, INC. | $148.12 | 2019-2022 | |
| Lilly USA, LLC | $145.78 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $101.55 | 2019-2021 | |
| Amgen INC. | $85.48 | 2020-2024 | Repatha, Otezla |
| Arbor Pharmaceuticals, INC. | $75.79 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $74.36 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.77 | 2020-2023 | Trulance, Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $55.34 | 2019-2021 | |
| Allergan, INC. | $51.33 | 2020 | |
| Janssen Pharmaceuticals, INC | $45.23 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $44.54 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $42.56 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $39.59 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $36.73 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.00 | 2019 | |
| Almatica Pharma LLC | $22.22 | 2023 | Gralise, Loreev Xr |
| Vivus LLC | $19.14 | 2022 | |
| Endo Pharmaceuticals INC. | $14.99 | 2019 | |
| Astellas Pharma US INC | $13.62 | 2020 | |
| Merck Sharp & Dohme LLC | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asya Benin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.